In a phase II study, 27 patients with metastatic breast cancer were treated with oral etoposide as second-line chemotherapy at a dose of 50 mg/m2/day for 21 days, which courses were repeated every 4 weeks. Twenty-one patients were evaluable for response, and twenty-five for toxicity. In two (10%) patients a partial response was observed with a duration of 60 and 122 weeks respectively, and seven patients (33%) showed stable disease. Gastrointestinal toxicity was usually mild, though relatively frequent. Anemia grade II and III was observed in 20 % of all courses (< 10% of all measurements), and leukopenia grade III and IV was observed in 22 % of all courses (< 10% of all measurements). There was one toxic death.
Introduction
The prognosis of patients with disseminated breast cancer refractory to or relapsing from first-line chemotherapy is poor. All currently applied cytotoxic drugs yield low response rates (10-30%) with a median duration of response of about 6 months or less and frequently considerable toxicity [1] . Therefore, new approaches are warranted. Because breast cancers contain usually a relatively low percentage of proliferating cells within the cell cycle, prolonged exposure to a cytotoxic drug is theoretically attractive.
Etoposide (VP16-213), a semisynthetic podophyllotoxin derivative with a wide antitumor activity, is a cell cycle phase-specific drug acting in the late S-and early G2-phase of the cell cycle with schedule dependency [2] . Activity of the drug is probably more related to duration of exposure to tumor cells rather than to the area under the curve (AUC) [3] [4] [5] . Etoposide has been used in clinical trials for approximately 20 years without clear efficacy in breast cancer, but recently there is renewed interest in this drug because of the application of new treatment schedules [6, 7] . There is clinical evidence that chronic daily administration of oral etoposide can induce responses in patients with different chemotherapy refractory solid tumors [8, 9] .
Out of the four breast cancer patients in a phase I trial using prolonged low-dose oral etoposide [8] , one had an objective response and one patient with non-measurable disease had a subjective response. Based on these data we initiated a phase II study with daily oral administration of etoposide as second-line chemotherapy in patients with metastatic breast cancer.
Patients and methods
Eligibility criteria of this study included patients with measurable or evaluable lesions, age less than 80 years, World Health Organization (WHO) performance score (PS) 2 or less, life expectancy of more than 2 months, serum bilirubin less than 20 gmol/1, WBC above 3.0 x 109/1, platelets above 100 x 109/1, no prior therapy with etoposide. Patients with a history of recent cardiac disease, or patients with metastases in the central nervous system, were excluded. Metastatic disease of all patients was considered resistant to previous endocrine therapy and to first-line chemotherapy. All patients gave oral informed consent before entering the study.
On-study evaluation consisted of medical history, physical examination, tumor measurements, complete blood count (Hb, WBC, platelets), automated blood chemistry, bonescan, bone and chest X-rays, and CT-scan or ultrasound of the liver in case of liver metastases. On follow-up complete blood count was performed weekly and response evaluation was performed after every second course.
Treatment consisted of etoposide 50 mg/m2/day, orally for three consecutive weeks, in a twentyeight day cycle. Responses and toxicity were defined according to WHO criteria. Duration of complete and partial response was measured from initiation of therapy till time of tumor progression.
Results
Twenty-seven patients entered the study. Patient characteristics are indicated in Table 1 . Two of the 27 patients were ineligible (PS: 3 and bilirubin 43 gmol/1). All 25 eligible patients were evaluable for toxicity. The total number of courses of etoposide administered was 90 (mean: 3.6; median 2, range 1-25). Gastrointestinal toxicity was usually mild. Twenty-two patients had no or only mild complaints of nausea (WHO grade 0-1), while four patients (16%) experienced nausea and vomiting grade II-III, for which reason one of them was hospitalized. Alopecia was often related to previous chemotherapy, while in three patients the first hair loss (grade II-III) was undoubtedly etoposide-induced. Leukopenia grade III and IV occurred in 15 patients (60%), in 22% of all courses, and in < 10% of all measurements; anemia grade II and III was observed in 9 patients (36%), in 20% of all courses, and in < 10% of all measurements. Mild to moderate thrombocytopenia was infrequent (grade I-II: in 3 % of all measurements). One patient died during the leukopenic period.
Four of the 25 eligible patients were not evaluable for response because of early withdrawal (within the first 3 weeks). Reasons to stop the treatment in these 4 patients were: severe nausea and vomiting (1), analysis of polyuria (1), anemia (1), and sudden death in a patient with an axillary thrombosis two weeks after start of therapy. No complete responses were observed in 21 patients evaluable for response. Two patients (10%) (95% confidence interval 1-30 %) achieved a partial response with a duration of 60 and 122 weeks, respectively. The first responding patient was treated before with hormonal therapy for 3 months without success, followed by 12 courses of FEC chemotherapy with stabilisation of the disease. During etoposide treatment the lytic bone metastases showed fair sclerosis. The second patient had been treated for three years with two lines of endocrine therapy, followed by 23 courses of CMF chemotherapy with a partial response. During etoposide therapy the pulmonary lesions showed a partial response and the bone lesions remained stable. Seven patients (33%) had stable disease with a median duration of 19 weeks (range 9+-32 weeks). Progressive disease from the start of treatment was observed in twelve patients. For the 21 evaluable patients the median time to progression was 2 months (mean: 4.3 months) and the median survival time was 8.3 months (mean: 11.3 months) (Fig. 1) .
Discussion
Treatment results of second-line chemotherapy in metastatic breast cancer are disappointing and remissions are usually of short duration [1] . There- Thus these short-term intravenous schemes of second-line chemotherapy with etoposide have shown only moderate activity in breast cancer, while toxicity was generally considered acceptable with myelosuppression emerging as the most frequent side effect. Treatment results of eight studies (including our study) using oral etoposide as second-line chemotherapy in metastatic breast cancer are also shown in Table 2 [8, 10, [17] [18] [19] [20] [21] . In the studies of Cavalli et al. [10] and Falkson et al. [17] using a high dose oral regimen for five days no responses were observed. However, because the cytotoxic effect of etoposide is more related to the duration of tumor cell exposure to the drug rather than to the AUC, prolonged exposure might theoretically result in an augmented anti-tumor effect [3] [4] [5] . In a phase I trial [8] one out of 4 patients with breast cancer responded to a long-term low-dose etoposide regimen. The recommended dose for following phase II studies was therefore 50 mg/m2/day for 21 days in a 28 day cycle. We performed a phase II study using this regimen but achieved only 10% remissions. Palombo et al. [18] , Martin et al. [19] , and Atienza et al. [21] performed similar studies in breast cancer patients pretreated with chemotherapy. They reported higher response rates, i.e. 22%, 35 % and 25 %, respectively (Table 2) . On the other hand Calvert et al. [20] reported the same response rate of 10% in a subgroup of 10 patients treated with 50 mg etoposide per day after previous chemotherapy. In this heterogeneous study higher response rates were observed in a subgroup of chemotherapy naive patients (45% response) and at a higher dose (100 mg/day) regimen (35 % response, regarding mainly patients not treated with chemotherapy before). When taking together all literature data, (chronic) oral etoposide treatment caused an objective response in 19% of 145 patients (Table 2) [8, 10, [17] [18] [19] [20] [21] , mostly of short duration. Responses can occur in all types of metastatic sites. The toxicity observed in our study is comparable with those of other studies with leucopenia as the most serious side effect. Also Calvert et al. [20] and Atienza et al. [21] reported the occurrence of toxic deaths, although this outpatient regimen appeared to be quite manageable.
In conclusion, second-line chemotherapy with etoposide has only moderate activity in patients with metastatic disease in the presence of significant but manageable toxicity. Newer agents such as taxol and taxotere might therefore be of greater interest [22, 23] , but maybe etoposide can be of greater value in combination with these or other active agents.
